{"groups":[{"description":"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nOther Name: HuLuc63\n\n•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24\n\nOther Name: REVLIMID\n\n•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8\n\nOther Name: Decadron\n\nElotuzumab: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nLenalidomide: 25 mg Oral; Days 1-21 days Cycles 1-24\n\nDexamethasone: 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8","id":"FG000","title":"Elo / Len / Dex"},{"description":"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nOther Name: HuLuc63\n\n•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24\n\nOther Name: REVLIMID\n\nElotuzumab: 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \\& 15 Cycles 3-8\n\nLenalidomide: 25 mg Oral; Days 1-21 days Cycles 1-24","id":"FG001","title":"Elo / Len"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"11"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"11"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}